초록 ▼

Methods of making coated implantable medical devices are provided. The methods include positioning a first layer comprising a bioactive on at least a portion of a structure, and positioning at least one porous layer over the first layer. The at least one porous layer has a thickness adequate to prov

Methods of making coated implantable medical devices are provided. The methods include positioning a first layer comprising a bioactive on at least a portion of a structure, and positioning at least one porous layer over the first layer. The at least one porous layer has a thickness adequate to provide a controlled release of the bioactive.

대표청구항 ▼

We claim: 1. A method of treating a human or veterinary patient, comprising implanting a vascular stent at a point of treatment within the vascular system of a human or veterinary patient, the vascular stent comprising a surface, a coating layer consisting of a parylene polymer posited on the surfa

We claim: 1. A method of treating a human or veterinary patient, comprising implanting a vascular stent at a point of treatment within the vascular system of a human or veterinary patient, the vascular stent comprising a surface, a coating layer consisting of a parylene polymer posited on the surface of the vascular stent, a layer comprising an immunosuppressive agent posited on at least a portion of the coating layer, and a porous layer comprising a second polymer overlaying the layer comprising the immunosuppressive agent. 2. The method of claim 1, wherein the surface of the vascular stent comprises stainless steel. 3. The method of claim 1, wherein about 0.01 mg to about 10 mg of the immunosuppressive agent is present per cm2 of the gross surface area of the vascular stent. 4. The method of claim 1, wherein about 0.1 mg to about 4 mg of the immunosuppressive agent is present per cm2 of the gross surface area of the vascular stent. 5. A method of inhibiting restenosis in a blood vessel, comprising deploying a vascular stent in a blood vessel, the vascular stent comprising a surface, a coating layer consisting of a parylene or a parylene derivative polymer posited on the surface of the vascular stent, a layer comprising an immunosuppressive agent posited on at least a portion of the coating layer, and a porous layer comprising a second polymer overlaying the layer comprising the immunosuppressive agent and having a thickness adequate to provide a controlled release of the immunosuppressive agent. 6. The method of claim 5, wherein the coating layer consists of the parylene derivative polymer. 7. The method of claim 5, wherein about 0.01 mg to about 10 mg of the immunosuppressive agent is present per cm2 of the gross surface area of the vascular stent. 8. The method of claim 5, wherein about 0.1 mg to about 4 mg of the immunosuppressive agent is present per cm2 of the gross surface area of the vascular stent. 9. The method of claim 1, wherein the thickness of the porous layer provides for a controlled release of the immunosuppressive agent through the porous layer. 10. A method of treating a human or veterinary patient, comprising implanting a vascular stent at a point of treatment within the vascular system of a human or veterinary patient, the vascular stent comprising a surface, a coating layer consisting of parylene or a parylene derivative polymer posited on the surface of the vascular stent, a layer comprising a second polymer attached to an immunosuppressive agent, and a porous layer comprising a third polymer overlaying the layer comprising the immunosuppressive agent and having a thickness adequate to provide a controlled release of the immunosuppressive agent. 11. The method of claim 10, wherein the coating layer consists of the parylene derivative polymer. 12. The method of claim 10, wherein the porous layer consists of the third polymer. 13. The method of claim 1, wherein the coating layer has a thickness of about 50,000 to 500,000 Angstroms. 14. The method of claim 1, wherein the porous layer has a thickness of about 5,000 to 250,000 Angstroms. 15. The method of claim 10, wherein 0.1 mg to 4 mg of the immunosuppressive agent is present per cm2 of gross surface area of the vascular stent. 16. The method of claim 1, wherein the coating layer has a thickness of about 50,000 to 500,000 Angstroms; the layer comprising the immunosuppressive agent contains a total of about 0.1 mg to 4 mg of immunosuppressive agent per cm2 of the gross surface area of the vascular stent and the porous layer has a thickness of about 5,000 to 250,000 Angstroms; and the vascular stent is about 10 mm to about 60 mm in length and is designed to expand to a diameter of about 2 mm to about 6 mm.